Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG206 in B-cell Lymphoid Malignancies
NCT05263739Phase 1Withdrawn
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of ESG206 in B-cell lymphoid malignancy (5 arms), sponsored by Shanghai Escugen Biotechnology Co., Ltd. Primary endpoint: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events. Planned start Dec 2025; status: withdrawn.
02
Drugs
ESG206
03
Conditions
B-cell lymphoid malignancy
Beyond the preview
Go deeper on NCT05263739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263739.